Clinical Trial Update: ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating ACVBP plus Rituximab in adults aged 18 to 59 with high-risk diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ACVBP regimen
• Rituximab (rituximab)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED